USE OF TAMOXIFEN FOR THE TREATMENT OF NEPHROGENIC SYSTEMIC FIBROSIS

Tamoxifen, is a selective modulator (competitive inhibition) of estrogen receptors, and it has antifibrotic properties which are used for treating retroperitoneal fibrosis, peritoneal sclerosis associated to peritoneal dialysis, desmoids tumors and in some cases of sclerodermia. In the present article, it is presented the hypothesis of a potential use of tamoxifen as a non immunosuppressant treatment for NSF in patients who have no contraindication for receiving it.